Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

777 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy.
Giles FJ, Abruzzese E, Rosti G, Kim DW, Bhatia R, Bosly A, Goldberg S, Kam GL, Jagasia M, Mendrek W, Fischer T, Facon T, Dünzinger U, Marin D, Mueller MC, Shou Y, Gallagher NJ, Larson RA, Mahon FX, Baccarani M, Cortes J, Kantarjian HM. Giles FJ, et al. Among authors: baccarani m. Leukemia. 2010 Jul;24(7):1299-301. doi: 10.1038/leu.2010.110. Epub 2010 Jun 3. Leukemia. 2010. PMID: 20520639 Free PMC article. Clinical Trial.
Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, Hughes T, Müller MC, Ezzeddine R, Countouriotis AM, Kantarjian HM. Hochhaus A, et al. Among authors: baccarani m. Leukemia. 2008 Jun;22(6):1200-6. doi: 10.1038/leu.2008.84. Epub 2008 Apr 10. Leukemia. 2008. PMID: 18401416
Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
le Coutre PD, Giles FJ, Hochhaus A, Apperley JF, Ossenkoppele GJ, Blakesley R, Shou Y, Gallagher NJ, Baccarani M, Cortes J, Kantarjian HM. le Coutre PD, et al. Among authors: baccarani m. Leukemia. 2012 Jun;26(6):1189-94. doi: 10.1038/leu.2011.323. Epub 2011 Nov 11. Leukemia. 2012. PMID: 22076466 Clinical Trial.
Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study.
Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, Cortes J, Baccarani M, Kantarjian HM. Giles FJ, et al. Among authors: baccarani m. Leukemia. 2013 Jan;27(1):107-12. doi: 10.1038/leu.2012.181. Epub 2012 Jul 5. Leukemia. 2013. PMID: 22763385 Clinical Trial.
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.
Jabbour E, le Coutre PD, Cortes J, Giles F, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Hughes TP, Saglio G, Radich JP, Kim DW, Martinelli G, Reynolds J, Woodman RC, Baccarani M, Kantarjian HM. Jabbour E, et al. Among authors: baccarani m. Leukemia. 2013 Apr;27(4):907-13. doi: 10.1038/leu.2012.305. Epub 2012 Nov 6. Leukemia. 2013. PMID: 23174881 Free PMC article.
Frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the European ENEST1st study.
Hochhaus A, Rosti G, Cross NC, Steegmann JL, le Coutre P, Ossenkoppele G, Petrov L, Masszi T, Hellmann A, Griskevicius L, Wiktor-Jedrzejczak W, Rea D, Coriu D, Brümmendorf TH, Porkka K, Saglio G, Gastl G, Müller MC, Schuld P, Di Matteo P, Pellegrino A, Dezzani L, Mahon FX, Baccarani M, Giles FJ. Hochhaus A, et al. Among authors: baccarani m. Leukemia. 2016 Jan;30(1):57-64. doi: 10.1038/leu.2015.270. Epub 2015 Oct 6. Leukemia. 2016. PMID: 26437782 Free PMC article. Clinical Trial.
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R. Hochhaus A, et al. Among authors: baccarani m. Leukemia. 2020 Apr;34(4):966-984. doi: 10.1038/s41375-020-0776-2. Epub 2020 Mar 3. Leukemia. 2020. PMID: 32127639 Free PMC article. Review.
777 results